Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical, woundcare and wound closure markets. Our strategy is based around:

  • Growth - Expanding our global presence
  • Innovation - Designing and developing leading products
  • Value - Offering cost-effective product solutions

Financial Calendar

Full Year End

31 December 2016

Interim Dividend Payment

28 October 2016

Half Year Results

14 September 2016

Trading Update

5 July 2016

Half Year End

30 June 2016

Final Dividend Payment

10 June 2016

AGM

2 June 2016
View Full Calendar

Financial Reports

2015 Annual Report

April 2016

Interim Report - 2015

October 2015

2014 Annual Report

April 2015

2014 Interim Report

September 2014

2013 Annual Report

April 2014

2013 Interim Report

September 2013
View All Reports

News

Winner- Partnership with the NHS
AMS wins Medilink North West Partnership with the NHS award 2016

Advanced Medical Solutions Group plc is pleased to announce they have been awarded the Partnership with the NHS award at the Medilink North West... Read More

View More News

Latest Financial Highlights

Summary

Financially, we remain very strong. In the first six months of the year, revenue increased by 20% to £39.2 million (2015 H1: £32.7 million), representing growth of 17% at constant currency and adjusted profit before tax increased by 16% to £9.5 million (2015 H1: £8.2 million). Our net cash position has increased to £41.1 million as at 30 June 2016 (31 December 2015: £34.2 million).

One of our key products, LiquiBand®, increased market share to 19% in the US tissue adhesive market and separately, in the US, following FDA approval in November 2015, we are now pleased to have initiated our first sales of RESORBA® sutures into this important market.

During the period we also launched two new ranges of foam dressings. Our antimicrobial foam dressing was launched into Europe following the CE mark approval that we received in August 2015.  This foam incorporates PHMB (polyhexamethylene biguanide), which has been shown to be effective against several bacteria and known hospital “super bugs”, strengthening our position in the antimicrobial advanced woundcare market. In addition, our foam portfolio was further increased by the launch of our new atraumatic silicone foam dressing range.

To further accelerate our growth beyond our own strong organic means, we continue to evaluate and consider potential acquisitions that are in line with the Group’s strategy.